Patents Assigned to Genentech
  • Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
    Patent number: 8389697
    Abstract: The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: March 5, 2013
    Assignee: Genentech, Inc.
    Inventors: Italo Beria, Michele Caruso, John A. Flygare, Vittoria Lupi, Rita Perego, Paul Polakis, Andrew Polson, Matteo Salsa, Susan D. Spencer, Barbara Valsasina
  • Protein product and method for reducing biomass-biomass interactions
    Patent number: 8383773
    Abstract: The invention includes a process for extracting a target protein from Escherichia coli (E. coli) cells that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.
    Type: Grant
    Filed: May 10, 2010
    Date of Patent: February 26, 2013
    Assignee: Genentech, Inc.
    Inventor: Richard L. Gehant
  • Method of treatment targeting HEPSIN
    Patent number: 8383123
    Abstract: Anti-HEPSIN monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: February 26, 2013
    Assignee: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Rajesh Vij
  • Phosphoinositide 3-kinase inhibitor compounds and methods of use
    Patent number: 8383620
    Abstract: Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R3 is a monocyclic heteroaryl group, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for modulating the activity of lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia-d for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: February 26, 2013
    Assignee: Genentech, Inc.
    Inventors: Tracy Bayliss, Irina Chuckowree, Adrian Folkes, Sally Oxenford, Nan Chi Wan, Georgette Castanedo, Richard Goldsmith, Janet Gunzner, Tim Heffron, Simon Mathieu, Alan Olivero, Steven Staben, Daniel P. Sutherlin, Bing-Yan Zhu
  • Nucleic acids encoding antibodies that bind factor D
    Patent number: 8383802
    Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: February 26, 2013
    Assignee: Genentech, Inc.
    Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
  • METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION TO TREAT TUMOR IMMUNITY
    Publication number: 20130045201
    Abstract: The present application relates to methods of using anti-PD-L1 antibodies to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: May 23, 2012
    Publication date: February 21, 2013
    Applicant: Genentech, Inc.
    Inventors: BRYAN IRVING, HENRY CHIU, HEATHER MAECKER, SANJEEV MARIATHASAN, SOPHIE M. LEHAR, YAN WU, JEANNE CHEUNG
  • METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO TREAT INFECTION RESULTING FROM T-CELL DYSFUNCTION
    Publication number: 20130045200
    Abstract: The present application relates to methods of using anti-PD-L1 antibodies to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: May 23, 2012
    Publication date: February 21, 2013
    Applicant: Genentech, Inc.
    Inventors: Bryan Irving, Henry Chiu, Heather Maecker, Sanjeev Mariathasan, Sophie M. Lehar, Yan Wu, Jeanne Cheung
  • ANTI-FGFR3 ANTIBODIES AND METHODS USING SAME
    Publication number: 20130046078
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: October 16, 2012
    Publication date: February 21, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • ANTI-PD-L1 ANTIBODIES AND ARTICLES OF MANUFACTURE
    Publication number: 20130045202
    Abstract: The present application relates to anti-PD-L1 antibodies, which have therapeutic use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: May 24, 2012
    Publication date: February 21, 2013
    Applicant: Genentech, Inc.
    Inventors: Bryan Irving, Henry Chiu, Heather Maecker, Sanjeev Mariathasan, Sophie M. Lehar, Yan Wu, Jeanne Cheung
  • Neuropilin antagonists
    Patent number: 8378080
    Abstract: Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: February 19, 2013
    Assignee: Genentech, Inc.
    Inventors: Ryan J. Watts, Yan Wu
  • C3b antibodies and methods for the prevention and treatment of complement-associated disorders
    Patent number: 8377437
    Abstract: The present invention concerns antibodies to c3b and the prevention and treatment of complement-associated disorder using such antibodies.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: February 19, 2013
    Assignee: Genentech, Inc.
    Inventor: Menno Van Lookeren Campagne
  • Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
    Patent number: 8377937
    Abstract: The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: February 19, 2013
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: Josef R. Bencsik, James F. Blake, Nicholas C. Kallan, Ian S. Mitchell, Keith L. Spencer, Dengming Xiao, Rui Xu, Christine Chabot, Jun Liang, Brian S. Safina
  • ENHANCED PROTEIN PURIFICATION THROUGH A MODIFIED PROTEIN A ELUTION
    Publication number: 20130041139
    Abstract: The present invention provides methods for purifying a polypeptide comprising a CH2/CH3 region, comprising binding the polypeptide to Protein A and eluting with a pH gradient starting at a low pH.
    Type: Application
    Filed: September 1, 2010
    Publication date: February 14, 2013
    Applicant: Genentech, Inc
    Inventors: Arick Brown, Christopher J. Dowd, Asha Nandini Radhamohan
  • PREDICTING RESPONSE TO A HER INHIBITOR
    Publication number: 20130039909
    Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
    Type: Application
    Filed: October 9, 2012
    Publication date: February 14, 2013
    Applicants: HOFFMANN-LA ROCHE INC., GENENTECH, INC.
    Inventors: Genentech, Inc., Hoffmann-La Roche Inc.
  • Anti-C5/C5a antibodies and methods of use
    Patent number: 8372404
    Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: February 12, 2013
    Assignee: Genentech, Inc.
    Inventors: Michael Fung, Meisheng Lu, William N. C. Sun, Cecily R. Y. Sun
  • Humanized anti-factor D antibodies and uses thereof
    Patent number: 8372403
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: February 12, 2013
    Assignee: Genentech, Inc.
    Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
  • METHODS FOR TREATING, DIAGNOSING, AND MONITORING LUPUS
    Publication number: 20130034544
    Abstract: Methods of identifying, diagnosing, and prognosing lupus, including certain subphenotypes of lupus, are provided, as well as methods of treating lupus, including certain subpopulations of patients. The methods provided are based on a set of alleles associated with systemic lupus erythematosus (SLE) risk loci including BLK, TNIP1, PRDM1, JAZF1, UHRF1BP1, IL1 O, IFIH1, CFB, CEC16A, IL12B and SH2B3 that contribute to SLE risk. Also provided are methods for identifying effective lupus therapeutic agents and predicting responsiveness to lupus therapeutic agents.
    Type: Application
    Filed: October 6, 2010
    Publication date: February 7, 2013
    Applicant: Genentech, Inc.
    Inventors: Timothy W. Behrens, Robert R. Graham
  • METHODS AND COMPOSITIONS FOR MODULATING PROSTASIN
    Publication number: 20130034570
    Abstract: The invention provides methods and compositions related to modulating prostasin.
    Type: Application
    Filed: September 13, 2012
    Publication date: February 7, 2013
    Applicant: Genentech, Inc.
    Inventors: Bin Fan, Daniel K. Kirchhofer
  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20130028862
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: January 20, 2012
    Publication date: January 31, 2013
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert D. Mass, William Novotny
  • IGF-1 to improve neural outcome
    Patent number: RE43982
    Abstract: A method of treating injuries to or diseases of the central nervous system that predominantly effects glia and/or non-cholinergic neuronal cells characterized in that it comprises the step of increasing the active concentration(s) of insulin-like growth factor 1 and/or analogues thereof in the central nervous system of the patient. The present invention also provides therapeutic compositions comprising insulin-like growth factor 1 and/or analogues thereof for administration to a patient at or following a neural insult, which compositions are useful in minimizing damage to the central nervous system that would otherwise occur following the insult.
    Type: Grant
    Filed: June 27, 2003
    Date of Patent: February 5, 2013
    Assignees: Genentech Inc., Auckland Uniservices Limited
    Inventors: Peter Gluckman, Karoly Nikolich